跳至主要内容
临床试验/NCT00983775
NCT00983775已完成不适用

Pharmacokinetic and Pharmacodynamic Profile of Rapid Acting Insulin Injected by Needle-free Jet-injection

Radboud University Medical Center2 个研究点 分布在 1 个国家目标入组 48 人开始时间: 2009年11月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
48
试验地点
2
主要终点
(time to) maximal glucose infusion rate

研究概览

简要总结

The purpose of this study is to compare the pharmacological profile of insulin administered with jet-injection with that of insulin injected with a conventional insulin pen.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 50 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Age 18-50 years
  • Body-mass index 18-28 kg/m2
  • Blood pressure <160/90 mmHg
  • Stable glycaemic control with HbA1c 6.5-9.0% (for patients with type 1 diabetes mellitus)
  • Duration of diabetes >1 year (for patients with type 1 diabetes mellitus)

排除标准

  • Inability to provide informed consent
  • Chronic use of medication other than oral contraceptives or thyroid hormone replacement therapy (with stable euthyroidism for at least 3 months)
  • Chronic use of medication other than insulin or low-dose angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) treatment (for patients with type 1 diabetes mellitus)
  • Type 2 diabetes in first-degree relatives (for healthy subjects)
  • History of a major cardiovascular disease event (myocardial infarction, stroke, symptomatic peripheral artery disease, coronary bypass surgery, percutaneous coronary or peripheral artery angioplasty)
  • Pregnancy
  • Macroalbuminuria, i.e. urinary albumin excretion >200 microg/min in collected urine sample or urinary albumin-to-creatinine ratio >300 mg/g in spot urine sample (for patients with type 1 diabetes mellitus)
  • Symptomatic diabetic neuropathy (for patients with type 1 diabetes mellitus)
  • Proliferative diabetic retinopathy (a history of proliferative retinopathy that was successfully treated with laser coagulopathy is not an exclusion criterion) (for patients with type 1 diabetes mellitus)

结局指标

主要结局

(time to) maximal glucose infusion rate

时间窗: 0-8 hours after insulin injection

次要结局

  • (time to) maximal insulin concentration(0-8 hours after insulin injection)

研究者

申办方类型
Other

研究点 (2)

Loading locations...

相似试验